Montpellier Cedex 5

• A Phase 3 Study to Evaluate AOC 1020 in Participants with FSHD Recruiting
  2025-521012-18-00 5 2026-04-13 Facioscapulohumeral Muscular Dystrophy (FSHD)
• A Phase II Study Evaluating the Efficacy and Safety of Inavolisib plus Ribociclib plus Fulvestrant Versus Placebo plus Ribociclib plus Fulve … Recruiting
  2025-523013-28-00 4 2026-04-07 Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced
• Phase III Study of Rilvegostomig in Combination withBevacizumab with or without Tremelimumab as First-lineTreatment of Hepatocellular Carcin … Recruiting
  2024-518210-81-00 5 2026-03-18 Advanced Hepatocellular Carcinoma
• A clinical study of islatravir and ulonivirine for people with HIV-1 who have not been treated before (MK-8591B-062) Recruiting
  2025-522519-40-00 10 2026-03-16 HIV
• DIAMOND Study - DIrect oral anticoagulant for Antithrombotic Management Of aortic bioprothesis implanted patients for valvular heart Disease … Recruiting
  2024-516643-64-00 5 2026-03-13 Aortic bioprothesis implanted patient for valvular heart disease
• A Long-term Extension Study of ORX750 in Participants with Narcolepsy and Idiopathic Hypersomnia Recruiting
  2025-522987-34-00 4 2026-03-13 Narcolepsy and Idiopathic Hypersomnia
• Visugromab, nivolumab and lenvatinib compared to double placebo and lenvatinib in unresectable or metastatic hepatocellular carcinoma post a … Recruiting
  2025-520675-86-00 4 2026-03-10 Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Li
• FAPI-PET value for the initial screening of pancreatic and biliary cancers (FAPDIG Study) Recruiting
  2024-517270-23-00 4 2026-03-05 Cholangiocarcinoma
• BEvacizumab plus Trifluridine/tipiracil in a bi-WEEkly administration to reduce grade 3-4 Neutropenia in patients with mCRC: A prospective, … Recruiting
  2024-520128-27-00 4 2026-03-04 colorectal adenocarcinoma
• Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide Recruiting
  2025-522015-42-00 10 2026-02-26 Chronic Hepatitis D Infection
• A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratum … Recruiting
  2025-520897-21-00 10 2026-02-25 Multiple Myeloma
• A trial to learn how safe Dato-DXd is and how well it works in people with NSCLC that has advanced after receiving osimertinib Recruiting
  2024-511362-37-00 5 2026-02-18 Non squamous non-small cell lung cancer (NSCLC)
• Lp(a) lowering study of pelacarsen (TQJ230) with background inclisiran in participants with elevated Lp(a) and established ASCVD Recruiting
  2024-516356-18-00 5 2026-02-17 Atherosclerotic cardiovascular disease (ASCVD)
• Tarlatamab vs standard of care chemotherapy in patients with pre-treated advanced, pulmonary or gastroenteropancreatic poorly differentiated … Recruiting
  2024-515948-23-00 5 2026-02-06 Advanced pulmonary or gastroenteropancreatic poorly differentiated neu
• A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has … Recruiting
  2025-521636-10-00 4 2026-02-04 Progressive Forms of Multiple Sclerosis (PMS)
• A Phase 2/3 clinical trial with zanzalintinib versus everolimus Recruiting
  2025-521043-20-00 10 2026-01-27 Neuroendocrine tumors
• Safety of Atezolizumab/Bevacizumab in liver transplanted patients with advanced hepatocellular carcinoma (IMMUNO-TH) Recruiting
  2024-514400-14-00 4 2026-01-23 liver transplanted patients with advanced hepatocellular carcinoma
• Randomized Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carc … Recruiting
  2024-515023-11-00 5 2026-01-22 Advanced Clear Cell Renal Cell Carcinoma
• FILOWM4-WaZaBi: "Open label phase 2 study evaluating the efficacy and tolerance of a zanubrutinib and BGB-11417 combination in patients prev … Recruiting
  2023-505781-28-00 4 2026-01-20 Patients with Waldenstrom macroglobulinemia and have received at least
• A Study to Compare the Efficacy and Safety of Prasinezumab with a placebo in Participants with Early-Stage Parkinson’s Disease Recruiting
  2025-522683-32-00 5 2026-01-15 Early-Stage Parkinson’s Disease (PD)
• Early detection of triple negative breast cancer relapse (CUPCAKE) Recruiting
  2022-501562-22-01 4 2026-01-05 Triple-negative breast cancer (TNBC) patients at high risk of relapse
• GRAALL 2024 - A 3-cohort Randomized Study evaluating the role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Tran … Recruiting
  2024-511437-35-00 10 2026-01-05 Patients aged 18-65 years old with newly diagnosed previously untreate
• Tolerance of local administration of cryopreserved autologous stromal vascular fraction combined with micrograft for the treatment of refrac … Recruiting
  2024-519740-32-00 4 2025-12-29 Crohn's disease
• Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) as First-Line Therapy in Adults with Transplant-Ineligible Primary Central Nervou … Recruiting
  2025-521144-38-00 4 2025-12-23 Primary Central Nervous System Lymphoma

Showing 169–192 of 846 trials